1. Pink Sheet
  2. >>Geography
  3. >>North America
  4. >>United States

CMS Coverage Group Changes Management, But Not Priorities

 
• By Ramsey Baghdadi

Director of CMS’ Coverage and Analysis Group Louis Jacques will leave the agency in March; his replacement, Deputy Tamara Syrek Jensen, will continue to make Coverage with Evidence Development a top priority.

A smooth transition is expected in CMS’ Coverage and Analysis Group following the departure of director Louis Jacques in March to the private sector.

Tamara Syrek Jensen, Jacques’ deputy, will take over his role in an acting capacity. It is a familiar role for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

US FDA Gives Leucovorin Unprecedented Path To New Claim Amid ‘Autism Crisis’

 
• By Bridget Silverman

The Trump Administration's autism campaign convinced GSK to submit an sNDA for its no-longer-marketed leucovorin as a treatment for a rare folate deficiency condition with promises to ensure insurance coverage for autism.

340B Reform Advocates Hail CBO Report, But ‘Scoreable’ Savings Still In Doubt

 
• By Michael McCaughan

The 340B program increases federal health care costs by encouraging the use of costlier medications, the Congressional Budget Office said. But the agency also did not provide a specific estimate of the impact.

Stealth’s Forzinity Accelerated Approval Shows US FDA Confirmatory Trial Status Flexibility

 
• By Sue Sutter

Stealth has until March 2026 to begin enrolling its confirmatory trial for its Barth syndrome drug elamipretide, marking a rare instance where a novel drug received accelerated approval even though the required postmarketing study was not underway.

ACIP Weakened COVID-19 Vaccine Advice, But Less Than Rhetoric May Suggest

 
• By Sarah Karlin-Smith

The new recommendations should not change insurance coverage, but the tone of the meeting frustrated many medical experts, because of the negative comments on the vaccines.

More from North America

Inexperience And Confusion: ACIP Struggles To End MMRV, Hep B Debates

 
• By Bridget Silverman

Confusion, inconsistency and strongly held views complicated the CDC's Advisory Committee on Immunization Practices' votes to change vaccine recommendations for the measles, mumps, rubella, varicella vaccine in young children and tabling of a vote on hepatitis B vaccine at birth.

US FDA Appears To Be Managing MAHA Well By Feeding Instead Of Receiving Priorities

 
• By Ramsey Baghdadi

The newly issued Make America Healthy Again strategy report suggests that FDA leaders are doing a good job of feeding ideas to the Trump Administration, rather than having the agency agenda dictated from above.

Stakeholders Warn Medicare Payment Proposals For Cell, Gene Therapy Could Hamper Access

 
• By Cathy Kelly

CMS proposals would reduce Medicare payments for cell and gene therapy manufacturing and preparation, which will further disincentivize outpatient or community-based treatment, advocates and sponsors said.